UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Clinical cancer research, 2018-06, Vol.24 (11), p.2631-2641

2018

Volltextzugriff (PDF)

Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3‐mimetics using virtual tumors calibrated with cell viability assays

CPT: pharmacometrics and systems pharmacology, 2024-07, Vol.13 (7), p.1252-1263

2024

Volltextzugriff (PDF)

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

CPT: pharmacometrics and systems pharmacology, 2021-11, Vol.10 (11), p.1396-1411

2021

Volltextzugriff (PDF)

Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor

Pharmaceutical research, 2013-10, Vol.30 (10), p.2640-2653

2013

Volltextzugriff (PDF)

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

The Lancet (British edition), 2020-12, Vol.396 (10266), p.1885-1894

2020

Volltextzugriff (PDF)

Peccary, a metaprogramming open-source R platform to improve pharmacometrics efficiency [version 1; peer review: 1 approved with reservations]

F1000 research, 2022, Vol.11, p.951

2022

Volltextzugriff (PDF)

How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example

Clinical pharmacology and therapeutics, 2023-02, Vol.113 (2), p.310-320

2023

Volltextzugriff (PDF)

Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mapping

Journal of pharmacokinetics and pharmacodynamics, 2022-12, Vol.49 (6), p.625-644

2022

Volltextzugriff (PDF)

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

Clinical pharmacology and therapeutics, 2021-03, Vol.109 (3), p.605-618

2021

Volltextzugriff (PDF)

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

The Lancet. Haematology, 2022-11, Vol.9 (11), p.e833-e843

2022

Volltextzugriff (PDF)

Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia

Cancer research communications, 2022-11, Vol.2 (11), p.1532-1544

2022

Volltextzugriff (PDF)

Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment

Journal of pharmacokinetics and pharmacodynamics, 2016-02, Vol.43 (1), p.29-43

2016

Volltextzugriff (PDF)

Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

The AAPS journal, 2018-03, Vol.20 (2), p.39-39, Article 39

2018

Volltextzugriff (PDF)

Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia

Cancer research communications, 2022-11, Vol.2 (11), p.1520-1531

2022

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I

European journal of cancer (1990), 2013-09, Vol.49 (13), p.2791-2797

2013

Volltextzugriff (PDF)

Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

The AAPS journal, 2018-03, Vol.20 (3), p.55-55, Article 55

2018

Volltextzugriff (PDF)

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients

Investigational new drugs, 2014-10, Vol.32 (5), p.985-994

2014

Volltextzugriff (PDF)

Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment

Journal of pharmacokinetics and pharmacodynamics, 2016-02, Vol.43 (1), p.13-27

2016

Volltextzugriff (PDF)

Modeling and simulation of cell populations interaction

Mathematical and computer modelling, 2009-06, Vol.49 (11), p.2104-2108

2009

Volltextzugriff (PDF)

Influence of the duration of intravenous drug administration on tumor uptake

Frontiers in oncology, 2013-01, Vol.3, p.192

2013

Volltextzugriff (PDF)

Abstract A192: PK/PD modeling-based optimization of administration schedule for the histone deacetylase inhibitor (HDACi) S78454/PCI-24781 in phase I

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A192-A192

2011

Volltextzugriff (PDF)

Quantitative Analysis of Melanocyte Migration in vitro Based on Automated Cell Tracking under Phase Contrast Microscopy Considering the Combined Influence of Cell Division and Cell-Matrix Interactions

Mathematical modelling of natural phenomena, 2010, Vol.5 (1), p.4-33

2010

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(12)
Pharmacology & Pharmacy
(10)
Models, Biological
(7)
Oncology
(7)
Pharmacology/toxicology
(7)
Adult
(6)
Biochemistry
(6)
Biomedical And Life Sciences
(6)
Biomedicine
(6)
Computer Simulation
(6)
Pharmacokinetics
(6)
Pharmacology
(6)
Pharmacy
(6)
Female
(5)
Male
(5)
Pharmacodynamics
(5)
Tumors
(5)
Biomedical Engineering And Bioengineering
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3‐mimetics using virtual tumors calibrated with cell viability assays

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Peccary, a metaprogramming open-source R platform to improve pharmacometrics efficiency [version 1; peer review: 1 approved with reservations]

How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example

Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mapping

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia

Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment

Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I

Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients

Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment

Modeling and simulation of cell populations interaction

Influence of the duration of intravenous drug administration on tumor uptake

Abstract A192: PK/PD modeling-based optimization of administration schedule for the histone deacetylase inhibitor (HDACi) S78454/PCI-24781 in phase I

Quantitative Analysis of Melanocyte Migration in vitro Based on Automated Cell Tracking under Phase Contrast Microscopy Considering the Combined Influence of Cell Division and Cell-Matrix Interactions

Suchergebnisse filtern